Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Update

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totaling 39,109 shares, an increase of 4,114.3% from the November 30th total of 928 shares. Based on an average daily volume of 189,317 shares, the days-to-cover ratio is currently 0.2 days. Currently, 4.0% of the company’s stock are sold short. Currently, 4.0% of the company’s stock are sold short. Based on an average daily volume of 189,317 shares, the days-to-cover ratio is currently 0.2 days.

Analysts Set New Price Targets

A number of research analysts have commented on SNSE shares. HC Wainwright downgraded shares of Sensei Biotherapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Insider Transactions at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, major shareholder James Peyer sold 3,507 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $7.96, for a total value of $27,915.72. Following the transaction, the insider directly owned 155,142 shares of the company’s stock, valued at $1,234,930.32. This represents a 2.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last quarter, insiders sold 27,907 shares of company stock worth $287,280. 23.20% of the stock is owned by insiders.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ SNSE traded up $0.06 during midday trading on Wednesday, reaching $9.27. 4,884 shares of the company traded hands, compared to its average volume of 61,420. The company has a market cap of $11.67 million, a price-to-earnings ratio of -0.48 and a beta of 0.32. Sensei Biotherapeutics has a 52 week low of $5.00 and a 52 week high of $18.35. The stock has a 50-day moving average price of $9.44 and a 200 day moving average price of $8.79.

Sensei Biotherapeutics (NASDAQ:SNSE) last announced its earnings results on Friday, November 14th. The company reported ($3.62) earnings per share for the quarter, beating the consensus estimate of ($4.11) by $0.49. As a group, analysts expect that Sensei Biotherapeutics will post -1.17 EPS for the current year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.